Pinz Capital Management’s Krystal Biotech KRYS Stock Holding History

Pinz Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,500	Closed	-$315K	–	178
2021 Q4	$315K	Buy	+4,500	New	+$262K	0.12%	172
2020 Q3	–	Sell	-18,600	Closed	-$770K	–	154
2020 Q2	$770K	Buy	+18,600	New	+$895K	0.35%	103

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pinz Capital Management's KRYS Position: Q1 2022 in Review

Pinz Capital Management sold out of Krystal Biotech (KRYS) in Q1 2022, closing a stake of 4,500 shares — an estimated $315K sold.

Pinz Capital Management first reported a position in KRYS in Q2 2020 and held it in 2 quarters. The position peaked at $770K in Q2 2020. 135 funds tracked by Wall St. Rank hold KRYS as of Q1 2022.

Pinz Capital Management reported no remaining Krystal Biotech position as of Q1 2022 after selling out during the quarter.
Pinz Capital Management sold 4,500 Krystal Biotech shares in Q1 2022, an estimated $315K.
Pinz Capital Management first reported a position in Krystal Biotech in Q2 2020 and held it in 2 quarters.
Pinz Capital Management's Krystal Biotech position peaked at $770K in Q2 2020.
135 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2022.

Based on Pinz Capital Management's 13F filing for Q1 2022, filed 16 May 2022.